BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
VALEANT PHARMACEUTICALS INTERNATIONAL (NY: VRX)
133.92 USD  -1.49 (-1.10%)
Streaming Delayed Price  /  Updated: 1:09 PM EDT, Apr 23, 2014  /  Add to My Watchlist      
(VRX) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
April 23, 2014
(Stock Blog Hub, 12/18/13)
Valeant Pharmaceuticals International (NYSE: VRX) may be the big exception in the drug business. Unlike other companies, it isn’t plagued by slow growth, patent issues or development expenses. Through a...(read more)
(Stock Blog Hub, 5/16/13)
Valeant Pharmaceuticals’ (VRX) first quarter 2013 earnings of $1.27 (excluding special items but including stock-based compensation expense) were short of the Zacks...(read more)
(market folly, 9/14/12)
We've seen past commentary from multiple managers on shares of Valeant Pharmaceuticals (VRX) and thought it was worth highlighting given that numerous respected managers own it. Hedge Fund...(read more)
Valeant Pharmaceuticals International (VRX) Company Overview

There is no analysis for VRX yet. But you can go to Wikinvest to help create one!


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here